الفهرس 
cover EnglishOnly 14 pages are availabe for public view
 |  | from | 199 |  |  |
| | | from | 199 | | |
Abstract
In Egypt Female Breast Cancer Ranks As The First Malignancy Affecting Females (37.5% In NCI Egypt ). Approximately 20% To 25% Of Breast Cancer Patients Present With Locally Advanced Disease. Methods : This Is A Prospective Study Including Fifty Two Female Postmenopausal Patients With Newly Diagnosed LABC, They Receive 4 Months Of Neoadjuvant Aromatase Inhibitor (Letrozole) 2.5 Mg Daily Followed By Clinical And Radiological Evaluation, If They Have At Least Partial Response, They Will Be Refered To Surgery. Results: Complete Remission Was Achieved In Four Patients (8.2%) And Thirty-One (63.3%) Had PR. There Was A Significant Reduction In The Ki-67 Level Following Neoadjuvant Hormonal Therapy And There Was A Significant Correlation Between The Clinical Response Rates And The Ki-67 Level. Conclusion : Neoadjuvant Endocrine Therapy Using Aromatase Inhibitors Could Be As An Alternative To Conventional Chemotherapy In Post-Menopausal Women With Strong Hormone Receptor Positive Breast Cancers. The Ki-67 Proliferative Marker Could Be Used As Predictive Marker Of Response To Neoadjuvant Hormonal Therapy. Recommendation : To Integrate The Ki-67 Data Into A Post-Treatment Model That Referred To The Preoperative Endocrine Prognostic Index (PEPI) To Determine Patients With Low Risk Of Relapse That Adjuvant Chemotherapy After Neoadjuvant Endocrine Therapy May Not Be Necessary. -Aromatase Inhibitors -Neoadjuvant -Locally Advanced Breast Cancer Keywords : Postmenopausal- ER/PR Positive- Her-2 Neu- Ki-67.